Kymera Therapeutics, Inc.

NasdaqGM:KYMR 주식 보고서

시가총액: US$3.1b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Kymera Therapeutics 관리

관리 기준 확인 2/4

Kymera Therapeutics' CEO는 Nello Mainolfi, Jun2019 에 임명되었습니다 의 임기는 4.58 년입니다. 총 연간 보상은 $ 9.67M, 6.6% 로 구성됩니다. 6.6% 급여 및 93.4% 보너스(회사 주식 및 옵션 포함). 는 $ 19.21M 가치에 해당하는 회사 주식의 1% 직접 소유합니다. 19.21M. 경영진과 이사회의 평균 재임 기간은 각각 3.1 년과 3.8 년입니다.

주요 정보

Nello Mainolfi

최고 경영자

US$9.7m

총 보상

CEO 급여 비율6.6%
CEO 임기5.3yrs
CEO 소유권1.0%
경영진 평균 재임 기간3.3yrs
이사회 평균 재임 기간3.8yrs

최근 관리 업데이트

Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

Jun 12
Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

Recent updates

Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results

Aug 11
Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up

Jul 14
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up

Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

Jun 12
Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth

May 03
We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth

Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith

Mar 21

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Feb 25
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking

Feb 17
Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up

Dec 29
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up

We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully

Nov 06
We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully

Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts

Aug 31
Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts

Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Aug 04
Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up

May 21
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up

We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely

Apr 16
We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely

Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

Dec 28
Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

Kymera KT-333 gets FDA orphan drug status for blood cancer subtype

Sep 15

Kymera initiated at buy at Jefferies on promise in oncology, autoimmune spaces

Aug 15

Kymera Therapeutics GAAP EPS of -$0.78 misses by $0.08, revenue of $11.51M misses by $3.46M

Aug 09

CEO 보상 분석

Nello Mainolfi 의 보수는 Kymera Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$158m

Mar 31 2024n/an/a

-US$155m

Dec 31 2023US$10mUS$640k

-US$147m

Sep 30 2023n/an/a

-US$167m

Jun 30 2023n/an/a

-US$158m

Mar 31 2023n/an/a

-US$159m

Dec 31 2022US$7mUS$600k

-US$155m

Sep 30 2022n/an/a

-US$154m

Jun 30 2022n/an/a

-US$139m

Mar 31 2022n/an/a

-US$124m

Dec 31 2021US$12mUS$571k

-US$100m

Sep 30 2021n/an/a

-US$79m

Jun 30 2021n/an/a

-US$58m

Mar 31 2021n/an/a

-US$48m

Dec 31 2020US$4mUS$454k

-US$55m

Sep 30 2020n/an/a

-US$53m

Jun 30 2020n/an/a

-US$57m

Mar 31 2020n/an/a

-US$52m

Dec 31 2019US$2mUS$362k

-US$41m

보상 대 시장: Nello 의 총 보상 ($USD 9.67M )은 US 시장( $USD 6.76M ).

보상과 수익: 회사가 수익성이 없는 동안 Nello 의 보상이 증가했습니다.

CEO

Nello Mainolfi (45 yo)

5.3yrs

테뉴어

US$9,670,542

보상

Dr. Nello Mainolfi, M.D., Ph D., is Co-Founder, President, Chief Executive Officer and Director at Kymera Therapeutics, Inc. since November 2019. Previously, at Kymera Therapeutics, Dr. Mainolfi served as...

리더십 팀

이름위치테뉴어보상소유권
Bruce Booth
Co-Founder & Independent Chairman9yrsUS$266.46k0%
$ 0
Nello Mainolfi
Co-Founder5.3yrsUS$9.67m1.02%
$ 31.6m
Bruce Jacobs
Chief Financial Officer5.2yrsUS$4.16m0.18%
$ 5.7m
Jeremy Chadwick
Chief Operating Officer1.3yrsUS$5.19m0.0090%
$ 280.3k
Ellen Chiniara
Chief Legal Officer & Corporate Secretary1.7yrsUS$4.97m0.0095%
$ 296.1k
Jared Gollob
Chief Medical Officer6yrsUS$3.47m0.085%
$ 2.6m
Karen Weisbach
Head of People & Culture2.3yrs데이터 없음데이터 없음
Juliet Williams
Head of Research3.3yrs데이터 없음데이터 없음

3.3yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: KYMR 의 관리팀은 경험 ( 3.1 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Bruce Booth
Co-Founder & Independent Chairman9yrsUS$266.46k0%
$ 0
Nello Mainolfi
Co-Founder4.8yrsUS$9.67m1.02%
$ 31.6m
John M. Maraganore
Independent Director2.7yrsUS$236.46k0%
$ 0
Felix Baker
Lead Independent Directorless than a year데이터 없음데이터 없음
Elena Ridloff
Independent Director3.5yrsUS$246.46k0%
$ 0
Leigh Morgan
Independent Director2.2yrsUS$246.46k0%
$ 0
Jeffrey Albers
Independent Director4.2yrsUS$241.46k0%
$ 0
Pamela Esposito
Independent Director4yrsUS$243.96k0%
$ 0
Victor Sandor
Independent Director1.8yrsUS$231.46k0%
$ 0
Gorjan Hrustanovic
Independent Director4.5yrsUS$236.46k0%
$ 0

3.8yrs

평균 재임 기간

51.5yo

평균 연령

경험이 풍부한 이사회: KYMR 의 이사회는 경험(평균 재직 기간 3.8 년)으로 간주됩니다.